ArticleStem cells (Dayton, Ohio)2011
Effective transplantation of photoreceptor precursor cells selected via cell surface antigen expression.
Article in Stem cells (Dayton, Ohio), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 7 citations in OpenAlex.
- Photoreceptor replacement: a disease-agnostic approach for the treatment of advanced retinal degeneration.Eye (London, England) · 2026Review
- Lineage tracing reveals photoreceptor precursor cell subpopulations that contribute to murine retinogenesis.Frontiers in cell and developmental biology · 2026Article
- Dynamic molecular and cellular characteristics of VSX2-positive retinal progenitor cells in human retinal organoids.Stem cell research & therapy · 2025Article
- Device-free isolation of photoreceptor cells from patient iPSC-derived retinal organoids.JCI insight · 2025Article
- Identification of the CDH18 gene associated with age-related macular degeneration using weighted gene co-expression network analysis.Frontiers in genetics · 2024Article
- Bankable human iPSC-derived retinal progenitors represent a valuable source of multipotent cells.Communications biology · 2023Article
- A treatment within sight: challenges in the development of stem cell-derived photoreceptor therapies for retinal degenerative diseases.Frontiers in transplantation · 2023Review
- A short-term chick embryoIndian journal of ophthalmology · 2022Article
- Generation of an RCVRN-eGFP Reporter hiPSC Line by CRISPR/Cas9 to Monitor Photoreceptor Cell Development and Facilitate the Cell Enrichment for Transplantation.Frontiers in cell and developmental biology · 2022Article
- Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma.Cell death & disease · 2021Article
- Nanotube-like processes facilitate material transfer between photoreceptors.EMBO reports · 2021Article
- A look into retinal organoids: methods, analytical techniques, and applications.Cellular and molecular life sciences : CMLS · 2021Review
- Longitudinal single-cell RNA-seq of hESCs-derived retinal organoids.Science China. Life sciences · 2021Article
- Retinal Organoid Technology: Where Are We Now?International journal of molecular sciences · 2021Review
- Review
- Outer Retinal Cell Replacement: Putting the Pieces Together.Translational vision science & technology · 2021Review
- Synaptic repair and vision restoration in advanced degenerating eyes by transplantation of retinal progenitor cells.Stem cell reports · 2021Article
- Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas.Molecular therapy. Methods & clinical development · 2021Article
- Comparison of Developmental Dynamics in Human Fetal Retina and Human Pluripotent Stem Cell-Derived Retinal Tissue.Stem cells and development · 2021Article
- Label-free microfluidic enrichment of photoreceptor cells.Experimental eye research · 2020Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Retinal degenerative diseases are a major cause of untreatable blindness. Stem cell therapy to replace lost photoreceptors represents a feasible future treatment. We previously demonstrated that postmitotic photoreceptor precursors expressing an NrlGFP transgene integrate into the diseased retina and restore some light sensitivity. As genetic modification of precursor cells derived from stem cell cultures is not desirable for therapy, we have tested cell selection strategies using fluorochrome-conjugated antibodies recognizing cell surface antigens to sort photoreceptor precursors. Microarray analysis of postnatal NrlGFP-expressing precursors identified four candidate genes encoding cell surface antigens (Nt5e, Prom1, Podxl, and Cd24a). To test the feasibility of using donor cells isolated using cell surface markers for retinal therapy, cells selected from developing retinae by fluorescence-activated cell sorting based on Cd24a expression (using CD24 antibody) and/or Nt5e expression (using CD73 antibody) were transplanted into the wild-type or Crb1(rd8/rd8) or Prph2(rd2/rd2) mouse eye. The CD73/CD24-sorted cells migrated into the outer nuclear layer, acquired the morphology of mature photoreceptors and expressed outer segment markers. They showed an 18-fold higher integration efficiency than that of unsorted cells and 2.3-fold higher than cells sorted based on a single genetic marker, NrlGFP, expression. These proof-of-principle studies show that transplantation competent photoreceptor precursor cells can be efficiently isolated from a heterogeneous mix of cells using cell surface antigens without loss of viability for the purpose of retinal stem cell therapy. Refinement of the selection of donorphotoreceptor precursor cells can increase the number of integrated photoreceptor cells,which is a prerequisite for the restoration of sight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.